Gout: Joints and beyond, epidemiology, clinical features, treatment and co-morbidities

Maturitas

Volumn 78, Issue 4, 2014, Pages 245-251

  Robinson, Philip C ^a,b   Horsburgh, Simon ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b GOLD COAST UNIVERSITY HOSPITAL   (Australia)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Chronic kidney disease; Diabetes mellitus; Diet; Gout; Hypertension; Urate

Indexed keywords

COLCHICINE; CORTICOSTEROID; CYTOKINE RECEPTOR ANTAGONIST; FEBUXOSTAT; INTERLEUKIN 1 INHIBITOR; PEGLOTICASE; UNCLASSIFIED DRUG; URATE; URICOSURIC AGENT; ANTIGOUT AGENT; ANTIINFLAMMATORY AGENT; INTERLEUKIN 1; URIC ACID;

ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; COMORBIDITY; DIABETES MELLITUS; DIET; DIET SUPPLEMENTATION; GENOTYPE ENVIRONMENT INTERACTION; GOUT; HEREDITY; HUMAN; HYPERTENSION; HYPERURICEMIA; MEDICATION COMPLIANCE; OBESITY; REVIEW; ANTAGONISTS AND INHIBITORS; COMPLICATION; INFLAMMATION; JOINT; METABOLISM; PATHOLOGY;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; COLCHICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; INFLAMMATION; INTERLEUKIN-1; JOINTS; URIC ACID;

EID: 84904750759     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2014.05.001     Document Type: Review

References (88)

1. D. Winnard, C. Wright, and W.J. Taylor et al. National prevalence of gout derived from administrative health data in Aotearoa New Zealand Rheumatology 51 2012 901 909
2. N. Dalbeth, and L. Stamp Hyperuricaemia and gout: time for a new staging system? Ann Rheum Dis 2014 10.1136/annrheumdis-2014-205304 [e-published April 9 2014]
3. N. Dalbeth, J. Collis, K. Gregory, B. Clark, E. Robinson, and F.M. McQueen Tophaceous joint disease strongly predicts hand function in patients with gout Rheumatology (Oxford) 46 2007 1804 1807
4. N.L. Kleinman, R.A. Brook, and P.A. Patel et al. The impact of gout on work absence and productivity Value Health 10 2007 231 237
5. N.L. Edwards, J.S. Sundy, A. Forsythe, S. Blume, F. Pan, and M.A. Becker Work productivity loss due to flares in patients with chronic gout refractory to conventional therapy J Med Econ 14 2011 10 15
6. P. Robinson, W. Taylor, and T. Merriman Systematic review of the prevalence of gout and hyperuricemia in Australia Intern Med J 42 2012 997 1007
7. B.A. Briesacher, S.E. Andrade, H. Fouayzi, and K.A. Chan Comparison of drug adherence rates among patients with seven different medical conditions Pharmacotherapy 28 2008 437 443
8. M. Doherty, T.L. Jansen, and G. Nuki et al. Gout: why is this curable disease so seldom cured Ann Rheum Dis 71 2012 1765 1770
9. C.F. Kuo, M.J. Grainge, C. Mallen, W. Zhang, and M. Doherty Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study Ann Rheum Dis 2014 10.1136/annrheumdis-2013-204463
10. N. Dalbeth, and K. Lindsay The patient's experience of gout: new insights to optimize management Curr Rheumatol Rep 14 2012 173 178
11. K. Ichida, H. Matsuo, and T. Takada et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia Nat Commun 3 2012 764
12. E.W. Campion, R.J. Glynn, and L.O. DeLabry Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study Am J Med 82 1987 421 426
13. V. Bhole, M. de Vera, M.M. Rahman, E. Krishnan, and H. Choi Epidemiology of gout in women: fifty-two-year followup of a prospective cohort Arthritis Rheum 62 2010 1069 1076
14. Y. Zhu, B.J. Pandya, and H.K. Choi Prevalence of gout and hyperuricemia in the US General Population Arthritis Rheum 63 2011 3136 3141
15. E. Smith, D. Hoy, and M. Cross et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study Ann Rheum Dis 2014 10.1136/annrheumdis-2013-204647
16. E. Roddy, and H.K. Choi Epidemiology of gout Rheum Dis Clin N Am 40 2014 155 175
17. T.R. Merriman Population heterogeneity in the genetic control of serum urate Semin Nephrol 31 2011 420 425
18. B.T. Emmerson, S.L. Nagel, D.L. Duffy, and N.G. Martin Genetic control of the renal clearance of urate: a study of twins Ann Rheum Dis 51 1992 375 377
19. E. Krishnan, C.N. Lessov-Schlaggar, R.E. Krasnow, and G.E. Swan Nature versus nurture in gout: a twin study Am J Med 125 2012 499 504
20. T.R. Merriman, and N. Dalbeth The genetic basis of hyperuricaemia and gout Joint Bone Spine 78 2011 35 40
21. A.M. Reginato, D.B. Mount, I. Yang, and H.K. Choi The genetics of hyperuricaemia and gout Nat Rev Rheumatol 8 2012 610 621
22. T.R. Merriman, H.K. Choi, and N. Dalbeth The genetic basis of gout Rheum Dis Clin N Am 40 2014 279 290
23. A. Kottgen, E. Albrecht, and A. Teumer et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations Nat Genet 45 2013 145 154
24. H.K. Choi, and G. Curhan Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study BMJ 336 2008 309 312
25. H.K. Choi, K. Atkinson, E.W. Karlson, W. Willett, and G. Curhan Alcohol intake and risk of incident gout in men: a prospective study Lancet 363 2004 1277 1281
26. H.K. Choi, K. Atkinson, E.W. Karlson, W. Willett, and G. Curhan Purine-rich foods, dairy and protein intake, and the risk of gout in men N Engl J Med 350 2004 1093 1103
27. K.L. Stanhope, J.M. Schwarz, and P.J. Havel Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies Curr Opin Lipidol 24 2013 198 206
28. G. Van den Berghe Fructose: metabolism and short-term effects on carbohydrate and purine metabolic pathways Progr Biochem Pharmacol 21 1986 1 32
29. H.K. Choi, W. Willett, and G. Curhan Coffee consumption and risk of incident gout in men: a prospective study Arthritis Rheum 56 2007 2049 2055
30. Y. Zhang, T. Neogi, C. Chen, C. Chaisson, D.J. Hunter, and H.K. Choi Cherry consumption and decreased risk of recurrent gout attacks Arthritis Rheum 64 2012 4004 4011
31. N. Dalbeth, R. Ames, and G.D. Gamble et al. Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: a proof-of-concept randomised controlled trial Ann Rheum Dis 71 2012 929 934
32. N. Dalbeth, and P. Gow Alcohol excess may be overemphasised in gout treated in secondary care N Z Med J 119 2006 U2270
33. M.L. Dansinger, J.A. Gleason, J.L. Griffith, H.P. Selker, and E.J. Schaefer Comparison of the atkins, ornish, weight watchers, and zone diets for weight loss and heart disease risk reduction: a randomized trial JAMA 293 2005 43 53
34. B. Knauper, S. Cheema, M. Rabiau, and O. Borten Self-set dieting rules: adherence and prediction of weight loss success Appetite 44 2005 283 288
35. M.A. McAdams DeMarco, J.W. Maynard, and A.N. Baer et al. Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: the Atherosclerosis Risk in Communities cohort study Arthritis Rheum 64 2012 121 129
36. M.A. McAdams-DeMarco, J.W. Maynard, A.N. Baer, L.W. Kao, A. Kottgen, and J. Coresh A urate gene-by-diuretic interaction and gout risk in participants with hypertension: results from the ARIC study Ann Rheum Dis 72 2013 701 706
37. H.K. Choi, L.C. Soriano, Y. Zhang, and L.A. Rodriguez Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study BMJ 344 2012 d8190
38. Y. Zhang, T. Neogi, C. Chen, C. Chaisson, D.J. Hunter, and H. Choi Low-dose aspirin use and recurrent gout attacks Ann Rheum Dis 73 2014 385 390
39. X. Gao, G. Curhan, J.P. Forman, A. Ascherio, and H.K. Choi Vitamin C intake and serum uric acid concentration in men J Rheumatol 35 2008 1853 1858
40. H.K. Choi, X. Gao, and G. Curhan Vitamin C intake and the risk of gout in men: a prospective study Arch Intern Med 169 2009 502 507
41. H.Y. Huang, L.J. Appel, and M.J. Choi et al. The effects of vitamin C supplementation on serum concentrations of uric acid: results of a randomized controlled trial Arthritis Rheum 52 2005 1843 1847
42. L.K. Stamp, J.L. O'Donnell, C. Frampton, J.M. Drake, M. Zhang, and P.T. Chapman Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: a pilot randomized controlled trial Arthritis Rheum 65 2013 1636 1642
43. T.R. Merriman, and N. Dalbeth Genetic and environmental risk factors in hyperuricaemia and common gout Curr Rheumatol Rev 7 2011 114 122
44. I.A. Prior, T.J. Welby, T. Ostbye, C.E. Salmond, and Y.M. Stokes Migration and gout: the Tokelau Island migrant study Br Med J (Clin Res Ed) 295 1987 457 461
45. M.H. Pillinger, and A.M. Abeles Such sweet sorrow: fructose and the incidence of gout Curr Rheumatol Rep 12 2010 77 79
46. R.J. Johnson, M.S. Segal, and Y. Sautin et al. Potential role of sugar (fructose) in the epidemic of hypertension, obesity and the metabolic syndrome, diabetes, kidney disease, and cardiovascular disease Am J Clin Nutr 86 2007 899 906
47. K. O'Dea Marked improvement in carbohydrate and lipid metabolism in diabetic Australian aborigines after temporary reversion to traditional lifestyle Diabetes 33 1984 596 603
48. T. Lyngdoh, P. Vuistiner, and P. Marques-Vidal et al. Serum uric acid and adiposity: deciphering causality using a bidirectional Mendelian randomization approach PLoS ONE 7 2012 e39321
49. N. Dalbeth, M.E. House, and G.D. Gamble et al. Population-specific influence of SLC2A9 genotype on the acute hyperuricaemic response to a fructose load Ann Rheum Dis 72 2013 1868 1873
50. N. Dalbeth, M.E. House, and G.D. Gamble et al. Population-specific effects of SLC17A1 genotype on serum urate concentrations and renal excretion of uric acid during a fructose load Ann Rheum Dis 73 2014 313 314
51. N. Dalbeth, M.E. House, and G.D. Gamble et al. Influence of the ABCG2 gout risk 141 K allele on urate metabolism during a fructose challenge Arthritis Res Ther 16 2014 R34
52. D. Khanna, P.P. Khanna, and J.D. Fitzgerald et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis Arthritis Care Res (Hoboken) 64 2012 1447 1461
53. L.K. Stamp Safety profile of anti-gout agents: an update Curr Opin Rheumatol 26 2014 162 168
54. E. Suresh, and P. Das Recent advances in management of gout QJM 105 2012 407 417
55. N. Schlesinger Anti-interleukin-1 therapy in the management of gout Curr Rheumatol Rep 16 2014 398
56. L.X. Chen, and H.R. Schumacher Gout: an evidence-based review J Clin Rheumatol 14 2008 55 62
57. K.R. Hande, R.M. Noone, and W.J. Stone Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency Am J Med 76 1984 47 56
58. N. Dalbeth, S. Kumar, L. Stamp, and P. Gow Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout J Rheumatol 33 2006 1646 1650
59. L.K. Stamp, W.J. Taylor, and P.B. Jones et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol Arthritis Rheum 64 2012 2529 2536
60. D.A. Ostrov, B.J. Grant, and Y.A. Pompeu et al. Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire Proc Natl Acad Sci USA 109 2012 9959 9964
61. P.T. Illing, J.P. Vivian, and N.L. Dudek et al. Immune self-reactivity triggered by drug-modified HLA-peptide repertoire Nature 486 2012 554 558
62. D. Khanna, J.D. Fitzgerald, and P.P. Khanna et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia Arthritis Care Res (Hoboken) 64 2012 1431 1446
63. N.L. Edwards Quality of care in patients with gout: why is management suboptimal and what can be done about it Curr Rheumatol Rep 13 2011 154 159
64. R. Terkeltaub Update on gout: new therapeutic strategies and options Nat Rev Rheumatol 6 2010 30 38
65. F. Rees, M. Hui, and M. Doherty Optimizing current treatment of gout Nat Rev Rheumatol 10 2014 271 283
66. L.K. Stamp, and P.T. Chapman Gout and its comorbidities: implications for therapy Rheumatology (Oxford) 52 2012 34 44
67. M.A. Fravel, and M.E. Ernst Management of gout in the older adult Am J Geriatr Pharmacother 9 2011 271 285
68. K. Pui, P.J. Gow, and N. Dalbeth Efficacy and tolerability of probenecid as urate-lowering therapy in gout; clinical experience in high-prevalence population J Rheumatol 40 2013 872 876
69. N. Schlesinger, U. Yasothan, and P. Kirkpatrick Pegloticase Nat Rev Drug Discov 10 2011 17 18
70. L.R. Harrold, S.E. Andrade, and B.A. Briesacher et al. Adherence with urate-lowering therapies for the treatment of gout Arthritis Res Ther 11 2009 R46
71. G. Reach Treatment adherence in patients with gout Joint Bone Spine 78 2011 456 459
72. D.H. Solomon, J. Avorn, R. Levin, and M.A. Brookhart Uric acid lowering therapy: prescribing patterns in a large cohort of older adults Ann Rheum Dis 67 2008 609 613
73. L.R. Harrold, K.M. Mazor, S. Velten, I.S. Ockene, and R.A. Yood Patients and providers view gout differently: a qualitative study Chronic Illn 6 2010 263 271
74. K. Spencer, A. Carr, and M. Doherty Patient and provider barriers to effective management of gout in general practice: a qualitative study Ann Rheum Dis 71 2012 1490 1495
75. N. Dalbeth, K.J. Petrie, and M. House et al. Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability Arthritis Care Res (Hoboken) 63 2011 1605 1612
76. P.C. Robinson, and H.R. Schumacher Jr. A qualitative and quantitative analysis of the characteristics of gout patient education resources Clin Rheumatol 32 2013 771 778
77. R. Fleischmann, B. Kerr, and L.T. Yeh et al. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia Rheumatology (Oxford) 2014 10.1093/rheumatology/ket487
78. N.L. Edwards, and A. So Emerging therapies for gout Rheum Dis Clin N Am 40 2014 375 387
79. D.I. Feig, B. Soletsky, and R.J. Johnson Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial JAMA 300 2008 924 932
80. N.L. Edwards The role of hyperuricemia and gout in kidney and cardiovascular disease Cleve Clin J Med 75 Suppl. 5 2008 S13 S16
81. K. Hughes, T. Flynn, J. de Zoysa, N. Dalbeth, and T.R. Merriman Mendelian randomization analysis associates increased serum urate, due to genetic variation in uric acid transporters, with improved renal function Kidney Int 85 2014 344 351
82. P.C. Robinson, T.R. Merriman, P. Herbison, and J. Highton Hospital admissions associated with gout and their co-morbidities in New Zealand and England 1999-2009 Rheumatology (Oxford) 52 2013 118 126
83. T.R. Mikuls, C.H. MacLean, and J. Olivieri Quality of care indicators for gout management Arthritis Rheum 50 2004 937 943
84. H.K. Choi, and E.S. Ford Haemoglobin A1c, fasting glucose, serum C-peptide and insulin resistance in relation to serum uric acid levels - the Third National Health and Nutrition Examination Survey Rheumatology (Oxford) 47 2008 713 717
85. Q. Liu, G. Gamble, K. Pickering, S. Morton, and N. Dalbeth Prevalence and clinical factors associated with gout in patients with diabetes and prediabetes Rheumatology (Oxford) 51 2012 757 759
86. A.G. Stack, A. Hanley, and L.F. Casserly et al. Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality QJM 106 2013 647 658
87. T.M. Palmer, B.G. Nordestgaard, and M. Benn et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: Mendelian randomisation analysis of two large cohorts BMJ 347 2013 4262
88. A. Parsa, E. Brown, and M.R. Weir et al. Genotype-based changes in serum uric acid affect blood pressure Kidney Int 81 2012 502 507